These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21386783)

  • 1. Quantitative imaging of (124)I with PET/ CT in pretherapy lesion dosimetry. Effects impairing image quantification and their corrections.
    Jentzen W; Freudenberg L; Bockisch A
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):21-43. PubMed ID: 21386783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (90)Y-PET/CT Imaging Quantification for Dosimetry in Peptide Receptor Radionuclide Therapy: Analysis and Corrections of the Impairing Factors.
    Fabbri C; Bartolomei M; Mattone V; Casi M; De Lauro F; Bartolini N; Gentili G; Amadori S; Agostini M; Sarti G
    Cancer Biother Radiopharm; 2015 Jun; 30(5):200-10. PubMed ID: 25860616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry?
    Bardiès M; Buvat I
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):5-20. PubMed ID: 21386782
    [No Abstract]   [Full Text] [Related]  

  • 4. Experimental investigation of factors affecting the absolute recovery coefficients in iodine-124 PET lesion imaging.
    Jentzen W
    Phys Med Biol; 2010 Apr; 55(8):2365-98. PubMed ID: 20360631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.
    Jentzen W; Hobbs RF; Stahl A; Knust J; Sgouros G; Bockisch A
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):884-95. PubMed ID: 20069293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.
    Sgouros G; Kolbert KS; Sheikh A; Pentlow KS; Mun EF; Barth A; Robbins RJ; Larson SM
    J Nucl Med; 2004 Aug; 45(8):1366-72. PubMed ID: 15299063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging.
    Jentzen W; Hoppenbrouwers J; van Leeuwen P; van der Velden D; van de Kolk R; Poeppel TD; Nagarajah J; Brandau W; Bockisch A; Rosenbaum-Krumme S
    J Nucl Med; 2014 Nov; 55(11):1759-65. PubMed ID: 25332440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of (124)I-PET in diagnosis and treatment of thyroid carcinoma.
    Lubberink M; Abdul Fatah S; Brans B; Hoekstra OS; Teule GJ
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):30-6. PubMed ID: 17657202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition settings for PET of 124I administered simultaneously with therapeutic amounts of 131I.
    Lubberink M; van Schie A; de Jong HW; van Dongen GA; Teule GJ
    J Nucl Med; 2006 Aug; 47(8):1375-81. PubMed ID: 16883019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET quantification performance of the oversize-volume-of-interest approach in the context of tumour dosimetry in radionuclide therapy planning.
    Hammersen N; Jentzen W; Stawitzki F; Herrmann K; Kersting D; Fragoso Costa P; Moraitis A
    Phys Med Biol; 2024 Jul; 69(16):. PubMed ID: 38925139
    [No Abstract]   [Full Text] [Related]  

  • 11. Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer.
    Sgouros G; Hobbs RF; Atkins FB; Van Nostrand D; Ladenson PW; Wahl RL
    Eur J Nucl Med Mol Imaging; 2011 May; 38 Suppl 1(Suppl 1):S41-7. PubMed ID: 21484384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of prompt gamma coincidence correction on absorbed dose estimation in differentiated thyroid cancer using 124I PET/CT imaging.
    Wierts R; Conti M; Claessen AGG; Herrmann K; Kemerink GJ; Binse I; Wildberger JE; Mottaghy FM; Backes WH; Jentzen W
    Nucl Med Commun; 2018 Dec; 39(12):1156-1164. PubMed ID: 30204643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer.
    Weber M; Binse I; Nagarajah J; Bockisch A; Herrmann K; Jentzen W
    Q J Nucl Med Mol Imaging; 2019 Sep; 63(3):235-252. PubMed ID: 31298014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron range-free and multi-isotope tomography of positron emitters.
    Beekman FJ; Kamphuis C; Koustoulidou S; Ramakers RM; Goorden MC
    Phys Med Biol; 2021 Mar; 66(6):065011. PubMed ID: 33578400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.
    Dewaraja YK; Wilderman SJ; Ljungberg M; Koral KF; Zasadny K; Kaminiski MS
    J Nucl Med; 2005 May; 46(5):840-9. PubMed ID: 15872359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretherapeutic dosimetry in patients affected by metastatic thyroid cancer using 124I PET/CT sequential scans for 131I treatment planning.
    Pettinato C; Spezi E; Nanni C; Grassetto G; Monari F; Allegri V; Civollani S; Cima S; Zagni P; Mazzarotto R; Colletti PM; Rubello D; Fanti S
    Clin Nucl Med; 2014 Aug; 39(8):e367-74. PubMed ID: 24978332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
    Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry.
    Prideaux AR; Song H; Hobbs RF; He B; Frey EC; Ladenson PW; Wahl RL; Sgouros G
    J Nucl Med; 2007 Jun; 48(6):1008-16. PubMed ID: 17504874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems.
    Jentzen W; Weise R; Kupferschläger J; Freudenberg L; Brandau W; Bares R; Burchert W; Bockisch A
    Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):611-23. PubMed ID: 17929014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
    Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A
    J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.